BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mankowski MC, Kinchen VJ, Wasilewski LN, Flyak AI, Ray SC, Crowe JE Jr, Bailey JR. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proc Natl Acad Sci U S A 2018;115:E82-91. [PMID: 29255018 DOI: 10.1073/pnas.1718441115] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Kalemera MD, Capella-Pujol J, Chumbe A, Underwood A, Bull RA, Schinkel J, Sliepen K, Grove J. Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins. J Gen Virol 2021;102. [PMID: 33147126 DOI: 10.1099/jgv.0.001512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Zhang C, Huang X, Chen S, Li Y, Li Y, Wang X, Tang J, Xia L, Lin Z, Luo W, Li T, Li S, Zhang J, Xia N, Zhao Q. Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid. Vaccine 2018;36:6761-71. [PMID: 30287156 DOI: 10.1016/j.vaccine.2018.09.035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
3 Bartlett ML, Griffin DE. Acute RNA Viral Encephalomyelitis and the Role of Antibodies in the Central Nervous System. Viruses 2020;12:E988. [PMID: 32899509 DOI: 10.3390/v12090988] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Laidlaw SM, Dustin LB. An HCV Vaccine on the Fly. J Infect Dis 2020;221:1216-8. [PMID: 31074788 DOI: 10.1093/infdis/jiz231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Veenhuis RT, Garliss CC, Bailey JR, Blankson JN. CD8 Effector T Cells Function Synergistically With Broadly Neutralizing Antibodies to Enhance Suppression of HIV Infection. Front Immunol 2021;12:708355. [PMID: 34394110 DOI: 10.3389/fimmu.2021.708355] [Reference Citation Analysis]
6 Keck ML, Wrensch F, Pierce BG, Baumert TF, Foung SKH. Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine. Front Immunol 2018;9:1194. [PMID: 29904384 DOI: 10.3389/fimmu.2018.01194] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
7 Skinner NE, Bailey JR. Broadly neutralizing antibodies against hepatitis C virus: location, location, location. J Hepatol 2020;72:604-6. [PMID: 32019681 DOI: 10.1016/j.jhep.2020.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Fallet B, Hao Y, Florova M, Cornille K, de Los Aires AV, Girelli Zubani G, Ertuna YI, Greiff V, Menzel U, Hammad K, Merkler D, Reddy ST, Weill JC, Reynaud CA, Pinschewer DD. Chronic Viral Infection Promotes Efficient Germinal Center B Cell Responses. Cell Rep 2020;30:1013-1026.e7. [PMID: 31995746 DOI: 10.1016/j.celrep.2019.12.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
9 Kalemera M, Mincheva D, Grove J, Illingworth CJR. Building a mechanistic mathematical model of hepatitis C virus entry. PLoS Comput Biol 2019;15:e1006905. [PMID: 30883541 DOI: 10.1371/journal.pcbi.1006905] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
10 Murin CD, Gilchuk P, Crowe JE Jr, Ward AB. Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development. Front Immunol 2021;12:808047. [PMID: 35082794 DOI: 10.3389/fimmu.2021.808047] [Reference Citation Analysis]
11 Atanasiu D, Saw WT, Cairns TM, Eisenberg RJ, Cohen GH. Using Split Luciferase Assay and anti-HSV Glycoprotein Monoclonal Antibodies to Predict a Functional Binding Site Between gD and gH/gL. J Virol 2021:JVI. [PMID: 33504603 DOI: 10.1128/JVI.00053-21] [Reference Citation Analysis]
12 Pfaff-Kilgore JM, Davidson E, Kadash-Edmondson K, Hernandez M, Rosenberg E, Chambers R, Castelli M, Clementi N, Mancini N, Bailey JR, Crowe JE Jr, Law M, Doranz BJ. Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening. Cell Rep 2022;39:110859. [PMID: 35613596 DOI: 10.1016/j.celrep.2022.110859] [Reference Citation Analysis]
13 Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. J Hepatocell Carcinoma 2020;7:45-76. [PMID: 32346535 DOI: 10.2147/JHC.S221187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
14 Chen F, Tzarum N, Wilson IA, Law M. VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design. Curr Opin Virol 2019;34:149-59. [PMID: 30884330 DOI: 10.1016/j.coviro.2019.02.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 15.0] [Reference Citation Analysis]
15 Brasher NA, Eltahla AA, Underwood A, Boo I, Rizzetto S, Walker MR, Rodrigo C, Luciani F, Maher L, Drummer HE, Tedla N, Lloyd AR, Bull RA. B cell immunodominance in primary hepatitis C virus infection. Journal of Hepatology 2020;72:670-9. [DOI: 10.1016/j.jhep.2019.11.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
16 Kinchen VJ, Cox AL, Bailey JR. Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine? Trends Microbiol 2018;26:854-64. [PMID: 29703495 DOI: 10.1016/j.tim.2018.04.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
17 Brasher NA, Adhikari A, Lloyd AR, Tedla N, Bull RA. Hepatitis C Virus Epitope Immunodominance and B Cell Repertoire Diversity. Viruses 2021;13:983. [PMID: 34070572 DOI: 10.3390/v13060983] [Reference Citation Analysis]
18 Lin T, Chi X, Liu X, Pan S, Chen W, Duan H, Zhang X, Yang W. Recombinant Full-Length Hepatitis C Virus E1E2 Dimer Elicits Pangenotypic Neutralizing Antibodies. Front Immunol 2022;13:831285. [DOI: 10.3389/fimmu.2022.831285] [Reference Citation Analysis]
19 Zheng H, Yang Z, Li B, Li H, Guo L, Song J, Hou D, Li N, Yang J, Wu Q, Sun M, Liu L. Single B cells reveal the antibody responses of rhesus macaques immunized with an inactivated enterovirus D68 vaccine. Arch Virol 2020;165:1777-89. [PMID: 32462286 DOI: 10.1007/s00705-020-04676-6] [Reference Citation Analysis]
20 Cox AL. Challenges and Promise of a Hepatitis C Virus Vaccine. Cold Spring Harb Perspect Med 2020;10:a036947. [PMID: 31548228 DOI: 10.1101/cshperspect.a036947] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
21 Kinchen VJ, Bailey JR. Defining Breadth of Hepatitis C Virus Neutralization. Front Immunol 2018;9:1703. [PMID: 30116237 DOI: 10.3389/fimmu.2018.01703] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
22 Kinchen VJ, Massaccesi G, Flyak AI, Mankowski MC, Colbert MD, Osburn WO, Ray SC, Cox AL, Crowe JE Jr, Bailey JR. Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance. J Clin Invest 2019;129:4786-96. [PMID: 31408439 DOI: 10.1172/JCI130720] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
23 Collett S, Torresi J, Earnest-silveira L, Christiansen D, Elbourne A, Ramsland PA. Probing and pressing surfaces of hepatitis C virus-like particles. Journal of Colloid and Interface Science 2019;545:259-68. [DOI: 10.1016/j.jcis.2019.03.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
24 May ME, Pohlmeyer CW, Kwaa AK, Mankowski MC, Bailey JR, Blankson JN. Combined Effects of HLA-B*57/5801 Elite Suppressor CD8+ T Cells and NK Cells on HIV-1 Replication. Front Cell Infect Microbiol 2020;10:113. [PMID: 32266164 DOI: 10.3389/fcimb.2020.00113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Christiansen D, Earnest-Silveira L, Grubor-Bauk B, Wijesundara DK, Boo I, Ramsland PA, Vincan E, Drummer HE, Gowans EJ, Torresi J. Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. Sci Rep 2019;9:9251. [PMID: 31239471 DOI: 10.1038/s41598-019-45461-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
26 Bozhanova NG, Flyak AI, Brown BP, Ruiz SE, Salas J, Rho S, Bombardi RG, Myers L, Soto C, Bailey JR, Crowe JE, Bjorkman PJ, Meiler J. Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-30865-9] [Reference Citation Analysis]
27 Velázquez-Moctezuma R, Galli A, Law M, Bukh J, Prentoe J. Hepatitis C Virus-Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance. J Infect Dis 2019;219:68-79. [PMID: 30102355 DOI: 10.1093/infdis/jiy481] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
28 Bailey JR, Barnes E, Cox AL. Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Gastroenterology. 2019;156:418-430. [PMID: 30268785 DOI: 10.1053/j.gastro.2018.08.060] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 18.3] [Reference Citation Analysis]
29 Toth EA, Chagas A, Pierce BG, Fuerst TR. Structural and Biophysical Characterization of the HCV E1E2 Heterodimer for Vaccine Development. Viruses 2021;13:1027. [PMID: 34072451 DOI: 10.3390/v13061027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Yi C, Xia J, He L, Ling Z, Wang X, Yan Y, Wang J, Zhao X, Fan W, Sun X, Zhang R, Ye S, Zhang R, Xu Y, Ma L, Zhang Y, Zhou H, Huang Z, Niu J, Long G, Lu J, Zhong J, Sun B. Junctional and somatic hypermutation-induced CX4C motif is critical for the recognition of a highly conserved epitope on HCV E2 by a human broadly neutralizing antibody. Cell Mol Immunol 2021;18:675-85. [PMID: 32235917 DOI: 10.1038/s41423-020-0403-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
31 Frumento N, Flyak AI, Bailey JR. Mechanisms of HCV resistance to broadly neutralizing antibodies. Curr Opin Virol 2021;50:23-9. [PMID: 34329953 DOI: 10.1016/j.coviro.2021.07.003] [Reference Citation Analysis]
32 Sepulveda-Crespo D, Resino S, Martinez I. Hepatitis C virus vaccine design: focus on the humoral immune response. J Biomed Sci 2020;27:78. [PMID: 32631318 DOI: 10.1186/s12929-020-00669-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
33 Schlotthauer F, McGregor J, Drummer HE. To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. Viruses 2021;13:805. [PMID: 33946211 DOI: 10.3390/v13050805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Wrensch F, Crouchet E, Ligat G, Zeisel MB, Keck ZY, Foung SKH, Schuster C, Baumert TF. Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design. Front Immunol 2018;9:1436. [PMID: 29977246 DOI: 10.3389/fimmu.2018.01436] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
35 Lavie M, Hanoulle X, Dubuisson J. Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies. Front Immunol 2018;9:910. [PMID: 29755477 DOI: 10.3389/fimmu.2018.00910] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 10.5] [Reference Citation Analysis]